First-pass extracted concept

ACE2 as a druggable target for limiting SARS-CoV-2 entry and replication

Candidate: concept label1 source documents5 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

As evidence accumulates, ACE2 appears a druggable target in the attempt to limit virus entry and replication.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1review2020Frontiers in Molecular BiosciencesDOI PubMed

1 evidence snippet 5 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1clinical uncertainty summarymixed2020Source 1DOI PubMed

Whether hypertension or ACE inhibitor and angiotensin receptor blocker use alters the fate of SARS-CoV-2 infection through effects on ACE2 density remains an open debate.

Claim 2mechanism summarysupports2020Source 1DOI PubMed

ACE2 serves as the initial cellular target of SARS-related coronaviruses including SARS-CoV-2.

Claim 3mechanism summarysupports2020Source 1DOI PubMed

SARS-CoV-2 engages ACE2 through spike protein subunit S1 for binding, while S2 induces membrane fusion and viral genome delivery.

Claim 4pathophysiology summarymixed2020Source 1DOI PubMed

Upon infection, ACE2 activity is reported to be reduced by downregulation or shedding, and these events might precipitate the cytokine storm of severe COVID-19.

Claim 5therapeutic strategy summarysupports2020Source 1DOI PubMed

The review describes ACE2-directed intervention strategies including receptor blockade with antibodies, small molecules, or peptides, and competitive neutralization with exogenously administered ACE2.